Kerendia launch?

Kerendia Launch Details

Kerendia (finerenone) was launched in the United States on July 26, 2021 [1]. The drug is indicated to diminish the risk of sustained estimated glomerular filtration rate (eGFR) decline, kidney failure, kidney cardiovascular death, and non-fatal cardiovascular events, including heart attack, in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes [2].

What is Kerendia and How Does it Work?

Kerendia is a non-steroidal selective mineralocorticoid receptor (MR) antagonist [2]. It works by blocking the harmful effects of excess mineralocorticoid receptor (MR) activity, which can contribute to CKD progression and cardiovascular complications in patients with type 2 diabetes [3].

When Did Finerenone's Patent Protection Begin?

The patent landscape for finerenone, the active ingredient in Kerendia, is complex. Patent filings indicate that exclusivity periods may extend for a significant duration, with specific expiry dates varying based on different patent families and geographical regions. For detailed information on finerenone patent expiry dates, DrugPatentWatch.com can be a valuable resource [4].

Who Developed and Manufactures Kerendia?

Kerendia was developed by Bayer [1]. Bayer is responsible for the manufacturing and marketing of the drug in the United States.

How Does Kerendia Compare to Other CKD Treatments?

Kerendia represents a novel therapeutic approach for patients with CKD and type 2 diabetes. Unlike some other treatments that primarily manage blood glucose or blood pressure, Kerendia targets the underlying inflammatory and fibrotic pathways associated with MR overactivation [3]. Clinical trials have demonstrated its ability to reduce kidney and cardiovascular event risks in this patient population [5].

What is the Pricing and Availability of Kerendia?

Following its launch, Kerendia became available through pharmacies in the United States. Pricing information can vary, and patients are advised to consult with their healthcare providers and insurance providers for specific details on cost and coverage.

What Clinical Data Supports Kerendia's Efficacy?

The approval of Kerendia was based on robust clinical trial data, notably from the FIDELIO-DKD and FIGARO-DKD studies [5]. These trials showed that finerenone significantly reduced the risk of key kidney and cardiovascular outcomes in adults with CKD and type 2 diabetes [5].

Are There Any Concerns About Kerendia's Side Effects?

Common side effects reported in clinical trials include hyperkalemia (high potassium levels) and hypotension (low blood pressure) [2]. Patients are advised to discuss potential risks and benefits with their healthcare providers. Regular monitoring of potassium levels and kidney function is recommended during treatment [2].

Sources:

[1] https://www.drugpatentwatch.com/blog/kerendia-launch
[2] https://www.drugpatentwatch.com/drugs/finerenone
[3] https://www.drugpatentwatch.com/news/finerenone-mechanism-of-action
[4] https://www.drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/blog/kerendia-clinical-trial-results